Ocular Therapeutix Inc (OCUL)

Feb 17, 2025

Legato Capital Management LLC Sells 34,695 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Feb 17, 2025

Feb 14, 2025

Ocular Therapeutix CEO gets new compensation package - MSN

Feb 14, 2025

Feb 14, 2025

Ocular Therapeutix Approves New CEO Compensation Package - TipRanks

Feb 14, 2025

Feb 13, 2025

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Feb 13, 2025

Feb 13, 2025

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives $17.00 Consensus Price Target from Brokerages - Defense World

Feb 13, 2025

Feb 11, 2025

Ocular Hypertension Clinical and Non-Clinical Studies, Key - openPR

Feb 11, 2025

Feb 11, 2025

How to Take Advantage of moves in (OCUL) - Stock Traders Daily

Feb 11, 2025

Feb 10, 2025

DEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire

Feb 10, 2025

Feb 08, 2025

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Donald Notman Sells 6,301 Shares - MarketBeat

Feb 08, 2025

Feb 07, 2025

The OCUL Stock Puzzle: Unraveling Ocular Therapeutix Inc’s Fluctuating Performance - The InvestChronicle

Feb 07, 2025

Feb 07, 2025

Analytical Overview: Ocular Therapeutix Inc (OCUL)’s Ratios Tell a Financial Story - The Dwinnex

Feb 07, 2025

Feb 06, 2025

Is Ocular Therapeutix Inc (OCUL) a good investment opportunity? - US Post News

Feb 06, 2025

Feb 06, 2025

Raymond James maintains $19 target on Ocular Therapeutix stock - MSN

Feb 06, 2025

Feb 05, 2025

Ocular Therapeutix Inc (OCUL) may enjoy gains as insiders got busy in the recent days - Knox Daily

Feb 05, 2025

Feb 05, 2025

Raymond James maintains $19 target on Ocular Therapeutix stock By Investing.com - Investing.com Canada

Feb 05, 2025

Feb 05, 2025

Ocular Therapeutix CFO Donald Notman sells $136,238 in stock By Investing.com - Investing.com Canada

Feb 05, 2025

Feb 04, 2025

Ocular Therapeutix CFO Donald Notman sells $136,238 in stock - Investing.com India

Feb 04, 2025

Feb 04, 2025

There is no way Ocular Therapeutix Inc (OCUL) can keep these numbers up - SETE News

Feb 04, 2025

Feb 04, 2025

Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) institutional investors lost 4.3% last week but have benefitted from longer-term gains - Simply Wall St

Feb 04, 2025

Feb 04, 2025

Ocular Therapeutix™ Announces Upcoming Presentations at the - GlobeNewswire

Feb 04, 2025

Feb 03, 2025

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting - The Manila Times

Feb 03, 2025

Feb 03, 2025

Ocular Therapeutix, Inc. Announces Presentations at Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting - Nasdaq

Feb 03, 2025

Feb 03, 2025

Revolutionary Eye Treatment Data: Ocular's OTX-TKI Takes Center Stage at Premier Medical Conference - StockTitan

Feb 03, 2025

Jan 31, 2025

Ocular Therapeutix (NASDAQ:OCUL) Shares Cross Below 200 Day Moving AverageHere's What Happened - MarketBeat

Jan 31, 2025

Jan 31, 2025

SG Americas Securities LLC Buys 26,511 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World

Jan 31, 2025

Jan 28, 2025

Ocular Therapeutix (NASDAQ:OCUL) Share Price Passes Below 200-Day Moving Average – Should You Sell? - Defense World

Jan 28, 2025

Jan 21, 2025

Advancements in Ocular Hypertension Clinical Trial Pipeline - GlobeNewswire

Jan 21, 2025

Jan 20, 2025

RoundAngle Advisors LLC Invests $1.70 Million in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Jan 20, 2025

Jan 20, 2025

Ocular Therapeutix (NASDAQ:OCUL) and Verona Pharma (NASDAQ:VRNA) Financial Contrast - Defense World

Jan 20, 2025

Jan 17, 2025

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jan 17, 2025

Jan 17, 2025

Ocular Therapeutix Grants Stock Options and RSU Awards to New Employee in Incentive Plan - StockTitan

Jan 17, 2025

Jan 16, 2025

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Jan 16, 2025

Jan 16, 2025

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Jan 16, 2025

Jan 15, 2025

Ocular Therapeutix (STU:0OT) Cash From Discontinued Investi - GuruFocus.com

Jan 15, 2025

Jan 15, 2025

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR - GlobeNewswire

Jan 15, 2025

Jan 14, 2025

Ocular Therapeutix progresses with AXPAXLI trials for eye diseases By Investing.com - Investing.com Canada

Jan 14, 2025

Jan 14, 2025

Ocular Therapeutix progresses with AXPAXLI trials for eye diseases - Investing.com India

Jan 14, 2025

Jan 14, 2025

Ocular Therapeutix Advances AXPAXLI Eye Treatment Trials with Strong Enrollment Milestone - StockTitan

Jan 14, 2025

Jan 13, 2025

Neuropathic Ocular Pain Market Is Booming Worldwide 2025-2032 | - openPR

Jan 13, 2025

Jan 11, 2025

Investors push Ocular Therapeutix (NASDAQ:OCUL) 6.3% lower this week, company's increasing losses might be to blame - Simply Wall St

Jan 11, 2025

Jan 09, 2025

Learn to Evaluate (OCUL) using the Charts - Stock Traders Daily

Jan 09, 2025

Jan 08, 2025

OCULOcular Therapeutix, Inc. Latest Stock News & Market Updates - StockTitan

Jan 08, 2025

Jan 08, 2025

Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation - The Manila Times

Jan 08, 2025

Jan 08, 2025

Ocular Therapeutix™ to Provide Corporate Update During 43rd - GlobeNewswire

Jan 08, 2025

Jan 08, 2025

Ocular Therapeutix CEO to Present AXPAXLI Trial Updates at J.P. Morgan Healthcare Conference - StockTitan

Jan 08, 2025